Hepion Pharmaceuticals
HEPA
HEPA was delisted on the 12th of May, 2025.
1 hedge funds and large institutions have $3.16M invested in Hepion Pharmaceuticals in 2015 Q2 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
707% more capital invested
Capital invested by funds: $391K → $3.16M (+$2.77M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.03M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SIM
Spark Investment Management
New York
|
-$40K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
-$3K |
| 3 |
TDC
Thompson Davis & Co
Richmond,
Virginia
|
-$2K |
| 4 |
BNP Paribas Financial Markets
Paris,
France
|
-$317 |
HEPA Hedge Fund Activity: Q2 2015 in Review
1 of the 3,730 institutional investors tracked by Wall St. Rank reported a position in Hepion Pharmaceuticals (HEPA) for Q2 2015, worth a combined $3.16M — up 707% from $391K a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new HEPA positions and 0 closed out — a net gain of 1 holder — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Vanguard Group, opening a new position worth an estimated $2.03M. The largest seller was Spark Investment Management, cutting an estimated $40K.
- 1 institutional investor held Hepion Pharmaceuticals (HEPA) as of Q2 2015, up from 0 in Q1 2015.
- Funds reported $3.16M of Hepion Pharmaceuticals stock for Q2 2015, up 707% quarter-over-quarter.
- 1 fund opened new Hepion Pharmaceuticals positions in Q2 2015 and 0 closed out, a net change of +1 holder.
- The largest Hepion Pharmaceuticals buyer in Q2 2015 was Vanguard Group, an estimated $2.03M added.
- The largest Hepion Pharmaceuticals seller in Q2 2015 was Spark Investment Management, an estimated $40K sold.
Based on aggregated 13F filings for Q2 2015.